Kiromic BioPharma, Inc. (KRBP)
Pre-market:
- Business Wire
Kiromic BioPharma Announces Reverse Stock Split
HOUSTON, March 10, 2023--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time today, March 10, 2023. Kiromic common stock will begi
- Business Wire
Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
HOUSTON, February 28, 2023--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces favorable safety results from the histopathology evaluation of a preclinical study of the pharmacology of KB-GDT-01 (trademark: Deltacel™) administered alone and in combination with a non-biologic
- Business Wire
Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote "FOR" All Proxy Proposals
HOUSTON, February 23, 2023--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that Institutional Shareholder Services (ISS) and Glass Lewis & Co. (Glass Lewis), two leading independent proxy advisory firms, have issued recommendations that Kiromic stockholders vote FOR all
